Corbus Pharmaceuticals Holdings, Inc.2024财年第三财季实现净利润-13.78百万美元，同比减少37.11%

市场透视11-11

11月11日，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）公布财报，公告显示公司2024财年第三财季净利润为-13.78百万美元，同比减少37.11%；其中营业收入为0.00美元，每股基本收益为-1.15美元。从资产负债表来看，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）总负债13.67百万美元，其中...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482076262?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482076262","market":"us","top_or_hot":-1,"title":"Corbus Pharmaceuticals Holdings, Inc.2024财年第三财季实现净利润-13.78百万美元，同比减少37.11%","media":"市场透视","content":"<div>\n<p>11月11日，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）公布财报，公告显示公司2024财年第三财季净利润为-13.78百万美元，同比减少37.11%；其中营业收入为0.00美元，每股基本收益为-1.15美元。从资产负债表来看，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）总负债13.67百万美元，其中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb36211&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corbus Pharmaceuticals Holdings, Inc.2024财年第三财季实现净利润-13.78百万美元，同比减少37.11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorbus Pharmaceuticals Holdings, Inc.2024财年第三财季实现净利润-13.78百万美元，同比减少37.11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb36211&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月11日，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）公布财报，公告显示公司2024财年第三财季净利润为-13.78百万美元，同比减少37.11%；其中营业收入为0.00美元，每股基本收益为-1.15美元。从资产负债表来看，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）总负债13.67百万美元，其中...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb36211&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRBP","symbol_name":"Corbus Pharmaceuticals Holdings, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb36211&s=b","article_id":"2482076262","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000033abb36211&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482076262","pubTimestamp":1731254425,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月11日，Corbus Pharmaceuticals Holdings, Inc.公布财报，公告显示公司2024财年第三财季净利润为-13.78百万美元，同比减少37.11%；其中营业收入为0.00美元，每股基本收益为-1.15美元。机构评级：截至2024年11月11日，当前有8家机构对Corbus Pharmaceuticals Holdings, Inc.目标价做出预测，其中目标均价为59.50美元，其中最低目标价为40.00美元，最高目标价为75.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CRBP":"Corbus Pharmaceuticals Holdings, Inc."},"translate_title":"Corbus Pharmaceuticals Holdings, Inc. achieved net profit of-$13.78 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 37.11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBP":1},"content_text":"11月11日，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）公布财报，公告显示公司2024财年第三财季净利润为-13.78百万美元，同比减少37.11%；其中营业收入为0.00美元，每股基本收益为-1.15美元。从资产负债表来看，Corbus Pharmaceuticals Holdings, Inc.（CRBP.US）总负债13.67百万美元，其中短期债务1.56百万美元，资产负债比为0.12，流动比率为0.14。机构评级：截至2024年11月11日，当前有8家机构对Corbus Pharmaceuticals Holdings, Inc.目标价做出预测，其中目标均价为59.50美元，其中最低目标价为40.00美元，最高目标价为75.00美元。公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。 该公司的产品线包括： CRB-701 ，一种下一代抗体药物偶联物 (ADC)，会针对癌细胞上 Nectin-4 的表达，释放细胞毒性有效负载；CRB-601 ，一种抗整合素单克隆抗体，可阻断癌细胞上表达的 TGF 的激活。 CRB-913 ，一种第二代外周限制性 CB1 受体反向激动剂，旨在治疗肥胖症。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482076262"}